Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy

Peter Noseworthy, Michael A. Rosenberg, Michael A. Fifer, Igor F. Palacios, Patricia A. Lowry, Jeremy N. Ruskin, Danita M. Sanborn, Michael H. Picard, Gus J. Vlahakes, Theofanie Mela, Saumya Das

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

We sought to assess the risk of sudden cardiac death (SCD) and ventricular arrhythmia after alcohol septal ablation (ASA) for obstructive hypertrophic cardiomyopathy. ASA is a nonsurgical alternative to septal myectomy for treatment of symptomatic, drug-refractory, obstructive hypertrophic cardiomyopathy. The effect of ASA on ventricular arrhythmia risk is not well established. We examined the rates of SCD among 89 patients treated with ASA. The secondary end point was ventricular tachycardia/ventricular fibrillation (VT/VF), appropriate implantable cardioverter defibrillator (ICD) therapy, or cardiac arrest after ASA among those with implanted ICDs or permanent pacemakers (n = 42). Patients were classified as either high-risk or low-risk on the basis of established clinical indications for ICD implantation. No mortality was attributable to SCD at a mean follow-up of 5.0 ± 2.3 years in the entire cohort. Among the 42 patients with an ICD or permanent pacemaker, 9 had documented VT/VF, cardiac arrest, or appropriate ICD therapy, resulting in an annual event rate of 4.9%/year. The annual event rate for VT/VF, cardiac arrest, or appropriate ICD therapy was 2.8%/year (4 of 29 patients) in low-risk patients and 13.4% in high-risk patients (5 of 13 patients). A 10-mm Hg increase in the immediate post-ASA gradient was associated with a hazard ratio of 2.66 for arrhythmic events (95% confidence interval 1.55 to 4.56, p <0.001). In conclusion, ASA was performed in patients with highly symptomatic, drug-refractory hypertrophic cardiomyopathy with no mortality attributable to SCD and an annual rate of VT/VF, cardiac arrest, or appropriate ICD therapy of 4.9%/year.

Original languageEnglish (US)
Pages (from-to)128-132
Number of pages5
JournalAmerican Journal of Cardiology
Volume104
Issue number1
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Hypertrophic Cardiomyopathy
Implantable Defibrillators
Cardiac Arrhythmias
Alcohols
Sudden Cardiac Death
Ventricular Fibrillation
Ventricular Tachycardia
Heart Arrest
Mortality
Therapeutics
Pharmaceutical Preparations
Confidence Intervals

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. / Noseworthy, Peter; Rosenberg, Michael A.; Fifer, Michael A.; Palacios, Igor F.; Lowry, Patricia A.; Ruskin, Jeremy N.; Sanborn, Danita M.; Picard, Michael H.; Vlahakes, Gus J.; Mela, Theofanie; Das, Saumya.

In: American Journal of Cardiology, Vol. 104, No. 1, 01.07.2009, p. 128-132.

Research output: Contribution to journalArticle

Noseworthy, P, Rosenberg, MA, Fifer, MA, Palacios, IF, Lowry, PA, Ruskin, JN, Sanborn, DM, Picard, MH, Vlahakes, GJ, Mela, T & Das, S 2009, 'Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy', American Journal of Cardiology, vol. 104, no. 1, pp. 128-132. https://doi.org/10.1016/j.amjcard.2009.02.056
Noseworthy, Peter ; Rosenberg, Michael A. ; Fifer, Michael A. ; Palacios, Igor F. ; Lowry, Patricia A. ; Ruskin, Jeremy N. ; Sanborn, Danita M. ; Picard, Michael H. ; Vlahakes, Gus J. ; Mela, Theofanie ; Das, Saumya. / Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy. In: American Journal of Cardiology. 2009 ; Vol. 104, No. 1. pp. 128-132.
@article{648e4a93c1604692b2a5d3f82d932a0a,
title = "Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy",
abstract = "We sought to assess the risk of sudden cardiac death (SCD) and ventricular arrhythmia after alcohol septal ablation (ASA) for obstructive hypertrophic cardiomyopathy. ASA is a nonsurgical alternative to septal myectomy for treatment of symptomatic, drug-refractory, obstructive hypertrophic cardiomyopathy. The effect of ASA on ventricular arrhythmia risk is not well established. We examined the rates of SCD among 89 patients treated with ASA. The secondary end point was ventricular tachycardia/ventricular fibrillation (VT/VF), appropriate implantable cardioverter defibrillator (ICD) therapy, or cardiac arrest after ASA among those with implanted ICDs or permanent pacemakers (n = 42). Patients were classified as either high-risk or low-risk on the basis of established clinical indications for ICD implantation. No mortality was attributable to SCD at a mean follow-up of 5.0 ± 2.3 years in the entire cohort. Among the 42 patients with an ICD or permanent pacemaker, 9 had documented VT/VF, cardiac arrest, or appropriate ICD therapy, resulting in an annual event rate of 4.9{\%}/year. The annual event rate for VT/VF, cardiac arrest, or appropriate ICD therapy was 2.8{\%}/year (4 of 29 patients) in low-risk patients and 13.4{\%} in high-risk patients (5 of 13 patients). A 10-mm Hg increase in the immediate post-ASA gradient was associated with a hazard ratio of 2.66 for arrhythmic events (95{\%} confidence interval 1.55 to 4.56, p <0.001). In conclusion, ASA was performed in patients with highly symptomatic, drug-refractory hypertrophic cardiomyopathy with no mortality attributable to SCD and an annual rate of VT/VF, cardiac arrest, or appropriate ICD therapy of 4.9{\%}/year.",
author = "Peter Noseworthy and Rosenberg, {Michael A.} and Fifer, {Michael A.} and Palacios, {Igor F.} and Lowry, {Patricia A.} and Ruskin, {Jeremy N.} and Sanborn, {Danita M.} and Picard, {Michael H.} and Vlahakes, {Gus J.} and Theofanie Mela and Saumya Das",
year = "2009",
month = "7",
day = "1",
doi = "10.1016/j.amjcard.2009.02.056",
language = "English (US)",
volume = "104",
pages = "128--132",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Ventricular Arrhythmia Following Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy

AU - Noseworthy, Peter

AU - Rosenberg, Michael A.

AU - Fifer, Michael A.

AU - Palacios, Igor F.

AU - Lowry, Patricia A.

AU - Ruskin, Jeremy N.

AU - Sanborn, Danita M.

AU - Picard, Michael H.

AU - Vlahakes, Gus J.

AU - Mela, Theofanie

AU - Das, Saumya

PY - 2009/7/1

Y1 - 2009/7/1

N2 - We sought to assess the risk of sudden cardiac death (SCD) and ventricular arrhythmia after alcohol septal ablation (ASA) for obstructive hypertrophic cardiomyopathy. ASA is a nonsurgical alternative to septal myectomy for treatment of symptomatic, drug-refractory, obstructive hypertrophic cardiomyopathy. The effect of ASA on ventricular arrhythmia risk is not well established. We examined the rates of SCD among 89 patients treated with ASA. The secondary end point was ventricular tachycardia/ventricular fibrillation (VT/VF), appropriate implantable cardioverter defibrillator (ICD) therapy, or cardiac arrest after ASA among those with implanted ICDs or permanent pacemakers (n = 42). Patients were classified as either high-risk or low-risk on the basis of established clinical indications for ICD implantation. No mortality was attributable to SCD at a mean follow-up of 5.0 ± 2.3 years in the entire cohort. Among the 42 patients with an ICD or permanent pacemaker, 9 had documented VT/VF, cardiac arrest, or appropriate ICD therapy, resulting in an annual event rate of 4.9%/year. The annual event rate for VT/VF, cardiac arrest, or appropriate ICD therapy was 2.8%/year (4 of 29 patients) in low-risk patients and 13.4% in high-risk patients (5 of 13 patients). A 10-mm Hg increase in the immediate post-ASA gradient was associated with a hazard ratio of 2.66 for arrhythmic events (95% confidence interval 1.55 to 4.56, p <0.001). In conclusion, ASA was performed in patients with highly symptomatic, drug-refractory hypertrophic cardiomyopathy with no mortality attributable to SCD and an annual rate of VT/VF, cardiac arrest, or appropriate ICD therapy of 4.9%/year.

AB - We sought to assess the risk of sudden cardiac death (SCD) and ventricular arrhythmia after alcohol septal ablation (ASA) for obstructive hypertrophic cardiomyopathy. ASA is a nonsurgical alternative to septal myectomy for treatment of symptomatic, drug-refractory, obstructive hypertrophic cardiomyopathy. The effect of ASA on ventricular arrhythmia risk is not well established. We examined the rates of SCD among 89 patients treated with ASA. The secondary end point was ventricular tachycardia/ventricular fibrillation (VT/VF), appropriate implantable cardioverter defibrillator (ICD) therapy, or cardiac arrest after ASA among those with implanted ICDs or permanent pacemakers (n = 42). Patients were classified as either high-risk or low-risk on the basis of established clinical indications for ICD implantation. No mortality was attributable to SCD at a mean follow-up of 5.0 ± 2.3 years in the entire cohort. Among the 42 patients with an ICD or permanent pacemaker, 9 had documented VT/VF, cardiac arrest, or appropriate ICD therapy, resulting in an annual event rate of 4.9%/year. The annual event rate for VT/VF, cardiac arrest, or appropriate ICD therapy was 2.8%/year (4 of 29 patients) in low-risk patients and 13.4% in high-risk patients (5 of 13 patients). A 10-mm Hg increase in the immediate post-ASA gradient was associated with a hazard ratio of 2.66 for arrhythmic events (95% confidence interval 1.55 to 4.56, p <0.001). In conclusion, ASA was performed in patients with highly symptomatic, drug-refractory hypertrophic cardiomyopathy with no mortality attributable to SCD and an annual rate of VT/VF, cardiac arrest, or appropriate ICD therapy of 4.9%/year.

UR - http://www.scopus.com/inward/record.url?scp=67649359494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649359494&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2009.02.056

DO - 10.1016/j.amjcard.2009.02.056

M3 - Article

C2 - 19576333

AN - SCOPUS:67649359494

VL - 104

SP - 128

EP - 132

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 1

ER -